Liver Cancer Clinical Trials in Massachusetts

31 recruiting studies across 1 city

Browse by City

All Trials in Massachusetts

Phase

Trial	Phase	Sponsor	Dist.
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years	Phase 4	Guerbet	<1 mi
National Liver Cancer Screening Trial	Phase 4	University of Texas Southwestern Medical Center	<1 mi
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer	—	Dana-Farber Cancer Institute	<1 mi
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)	N/A	ABK Biomedical	<1 mi
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer	Phase 2	Massachusetts General Hospital	<1 mi
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma	Phase 2	Allison O'Neill, MD	<1 mi
Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases	Early 1	Dana-Farber Cancer Institute	<1 mi
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations	Phase 1	Tyra Biosciences, Inc	<1 mi
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors	Phase 1/2	Children's Oncology Group	<1 mi
Psychoeducational Intervention for Patients With Hepatocellular Carcinoma	N/A	Massachusetts General Hospital	<1 mi
Stereotactic Magnetic Resonance Guided Radiation Therapy	N/A	Dana-Farber Cancer Institute	<1 mi
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis	Phase 2	Genentech, Inc.	<1 mi
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors	Phase 1/2	ModeX Therapeutics, An OPKO Health Company	<1 mi
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER	Phase 1/2	Massachusetts General Hospital	<1 mi
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI	N/A	VA Office of Research and Development	<1 mi
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery	Phase 2	National Cancer Institute (NCI)	<1 mi
Jump: MR Simulation For Radiation Therapy Master Protocol	N/A	Brigham and Women's Hospital	<1 mi
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies	Phase 1	SEED Therapeutics, Inc.	<1 mi
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy	Phase 3	Pierre Fabre Medicament	<1 mi
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer	Phase 2	AstraZeneca	<1 mi
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma	Phase 1/2	Eureka Therapeutics Inc.	<1 mi
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors	Phase 1/2	Tango Therapeutics, Inc.	<1 mi
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors	Phase 1	Exelixis	<1 mi
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment	—	Fresenius Kabi	<1 mi
SIRT With Tremelimumab and Durvalumab for Resectable HCC	Phase 1	Jiping Wang, MD, PhD	<1 mi
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors	Phase 1/2	DualityBio Inc.	<1 mi
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis	—	Massachusetts General Hospital	1 mi
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives	—	Sanguine Biosciences	9 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry	—	Massive Bio, Inc.	39 mi
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy	Phase 1/2	7 Hills Pharma, LLC	41 mi
Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC	Phase 2	Brown University	41 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.